Optibrium Introduces AI Technologies to Help Guide Drug Discovery

October 10, 2019
Pharmaceutical Technology Editors

Developer of software for drug discovery, Optibrium, has announced in an Oct. 10, 2019 press release the introduction of its Augmented Chemistry services, which incorporate artificial intelligence technologies to help guide drug discovery.

Developer of software for drug discovery, Optibrium, has announced in an Oct. 10, 2019 press release the introduction of its Augmented Chemistry services, which incorporate artificial intelligence technologies to help guide drug discovery.

The newly introduced services have been based on Alchemite, which is a deep learning capability for data imputation. Developed in collaboration with Intelligens, Alchemite is a machine-learning approach that simultaneously learns across all experimental endpoints.

“Optibrium has an extensive track record of successfully introducing and delivering cutting-edge technologies to drug discovery, and our intimate knowledge of the unique challenges of drug discovery and the underlying data enable us to go beyond the hype and deliver results that make a difference,” said Matthew Segall, Optibrium’s chief executive officer, in the press release. “After successfully demonstrating its capabilities in collaboration with our partners, we’re excited to now be able to bring Augmented Chemistry services to our global customer base.”

Source: Optibrium